In this Expert Interview, Lisa Carey, MD, discusses the biologic differences that underlie differences in breast tumor behavior and outcomes. Medscape Hematology-Oncology
Bevacizumab has shown significant single-agent activity in relapsed ovarian cancer in 2 phase 2 trials, prompting further studies of this disease. Medscape Medical News
Read more about this interesting case of 39-year-old man with abdominal pain, jaundice, diarrhea, weakness and weight loss. Nature Clinical Practice Gastroenterology & Hepatology
Most current discovery strategies provide no clue as to whether proteins of interest are accessible, in human tissues, to suitable high-affinity ligands,such as systemically delivered MAbs. Expert Review of Proteomics
In this Expert Interview from ASCO 2008, Dr. Robert Motzer discusses the evolving role of mTOR inhibition in the treatment of renal cell carcinoma, with a focus on the newest agent in the class. Medscape Hematology-Oncology
